603566.SHG Pulike Biological Engineering
- Market cap
- CNY 3.23B
- P/E
- 30.1x
- P/B
- 1.27x
- ROE
- 4.2%
- Dividend yield
- 6.36%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603566.SHG undervalued?
Graham number603566.SHG trades 30.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pulike Biological Engineering fundamental analysis
No fundamental analysis for Pulike Biological Engineering yet.
Pulike Biological Engineering stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pulike Biological Engineering
Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for livestock, poultry, and pets. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.
Full company profilePulike Biological Engineering financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pulike Biological Engineering annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 583M | 530M | 608M | 663M | 929M | 1.10B | 1.23B | 1.25B | 1.04B | 1.09B | 984M |
| Gross Profit | 415M | 362M | 408M | 406M | 597M | 719M | 770M | 764M | 637M | 653M | 546M |
| Operating Income | 183M | 108M | 137M | 107M | 217M | 285M | 177M | 193M | 97.8M | 190M | 112M |
| EBITDA | 259M | 174M | 196M | 168M | 313M | 344M | 253M | 288M | 218M | 330M | 87.1M |
| Net Income | 188M | 114M | 136M | 109M | 217M | 244M | 168M | 175M | 92.8M | 185M | 106M |
| EPS | 0.59 | 0.36 | 0.42 | 0.34 | 0.68 | 0.78 | 0.52 | 0.50 | 0.27 | 0.53 | 0.31 |
| Balance Sheet | |||||||||||
| Total Assets | 1.74B | 1.81B | 1.90B | 1.91B | 2.03B | 2.17B | 3.39B | 3.26B | 3.10B | 3.24B | 3.10B |
| Total Liabilities | 256M | 236M | 268M | 247M | 319M | 368M | 588M | 538M | 471M | 500M | 443M |
| Shareholders' Equity | 1.48B | 1.57B | 1.64B | 1.66B | 1.71B | 1.80B | 2.80B | 2.72B | 2.63B | 2.61B | 2.55B |
| Cash & Short-term Investments | 429M | 263M | 451M | 611M | 519M | 244M | 972M | 725M | 686M | 137M | 255M |
| Total Debt | 45.7M | 27.0M | 12.7M | - | - | - | 9.69M | 1.06M | 20.2M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 253M | 141M | 126M | 140M | 262M | 213M | 228M | 283M | 269M | 356M | - |
| Capital Expenditure | 73.8M | 59.3M | 53.6M | 85.2M | 177M | 318M | 357M | 305M | 121M | 75.0M | 41.8M |
| Free Cash Flow | 179M | 81.6M | 72.7M | 54.9M | 84.7M | -105M | -124M | -22.2M | 148M | 281M | 154M |
| Ratios | |||||||||||
| ROE | 12.7% | 7.3% | 8.3% | 6.6% | 12.7% | 13.6% | 6.0% | 6.4% | 3.5% | 7.1% | 4.2% |
| ROA | 10.8% | 6.3% | 7.1% | 5.7% | 10.7% | 11.3% | 5.0% | 5.3% | 3.0% | 5.7% | 3.4% |
| Net Profit Margin | 32.2% | 21.5% | 22.3% | 16.5% | 23.3% | 22.2% | 13.6% | 13.9% | 8.9% | 17.0% | 10.8% |
| Debt to Equity | 0.03x | 0.02x | 0.01x | - | - | - | 0.00x | 0.00x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pulike Biological Engineering dividends
- Dividend yield
- 6.36%
- Forward dividend
- 0.60 CNY
- Payout ratio
- 110.9%
- Ex-dividend date
- Jun 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 205M | 0.59 | 110.9% |
| 2024 | CNY 138M | 0.40 | 148.5% |
| 2023 | CNY 225M | 0.64 | 128.9% |
| 2022 | CNY 63.6M | 0.20 | 37.9% |
| 2021 | CNY 157M | 0.50 | 64.4% |
| 2020 | CNY 63.2M | 0.20 | 29.2% |
| 2019 | CNY 96.0M | 0.30 | 87.9% |
| 2018 | CNY 64.7M | 0.20 | 47.7% |
| 2017 | CNY 64.3M | 0.20 | 56.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on May 31, 2016.
Who owns Pulike Biological Engineering
- Insiders 46.57%
- Institutions 1.94%
- Public & others 51.49%
- Shares outstanding 346M
- Free float 207M
Pulike Biological Engineering company profile
- Company name
- Pulike Biological Engineering
- Ticker
- 603566.SHG
- ISIN
- CNE1000025N0
- Exchange
- Shanghai Stock Exchange
- Listed since
- May 11, 2015
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,519
- Fiscal year end
- December
- Address
- No.15 Zhenghe Road, Luoyang, China, 471000
- Phone
- 86 379 6328 2386
- Website
- pulike.com.cn
About Pulike Biological Engineering
Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for livestock, poultry, and pets. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.
Pulike Biological Engineering management
6- Mr. Wei HuMD & Director · born 1973
- Ms. Lian Feng PeiCFO & Director · born 1973
- Mr. Rui ZhaoSecretary of the Board & Director · born 1984
- Dr. Ke Gong Tian Ph.D.Deputy General Manager · born 1964
- Ms. Bing HanDeputy General Manager · born 1981
- Fang Yuan ChenAccounting Supervisor